2. Search Result
Search Result
Results for "

Bone cancer

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

3

Screening Libraries

2

Biochemical Assay Reagents

2

Peptides

4

Inhibitory Antibodies

20

Natural
Products

5

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106431
    Olpadronic acid

    Olpadronate; OLP

    		 Others Metabolic Disease Cancer
    Olpadronic acid (Olpadronate) is an orally active amino-bisphosphonate and inhibits bone resorption. Olpadronic acid also prevents bone destruction and tumor growth in the skeletal prostate cancer mouse model. Olpadronic acid can be used for research of osteoporosis, malignancies and rheumatoid arthritis .
    Olpadronic acid
  • HY-33299
    Serpin B9-IN-1

    BTCA

    		 Biochemical Assay Reagents Cancer
    Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .
    Serpin B9-IN-1
  • HY-13738
    Raloxifene
    10+ Cited Publications

    Keoxifene; LY156758 free base; LY139481

    		 Estrogen Receptor/ERR Cancer
    Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    Raloxifene
  • HY-147011
    FTO-IN-7

    		Fat Mass and Obesity-associated Protein (FTO) Cancer
    FTO-IN-7 is an inhibitor of FTO. FTO-IN-7 can be used in study Alzheimer's diseases, breast cancers, small-cell lung cancers,a human bone marrow striated muscle cancer, a pancreatic cancer, malignant glioblastoma .
    FTO-IN-7
  • HY-P99029
    Magrolimab
    2 Publications Verification

    Hu5F9-G4

    		 CD47 Cancer
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
    Magrolimab
  • HY-W193545A
    ERG240
    3 Publications Verification

    		 Others Inflammation/Immunology Cancer
    ERG240 is an oral active branched-chain amino acid aminotransferase 1 (BCAT1) inhibitor. ERG240 can be used for the research of cancer, rheumatoid arthritis, and bone disease .
    ERG240
  • HY-13507
    Lumiracoxib

    COX-189

    		 COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib
  • HY-134259
    MEISi-2

    		HOXA Cancer
    MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .
    MEISi-2
  • HY-13738R
    Raloxifene (Standard)

    		Estrogen Receptor/ERR Cancer
    Raloxifene (Standard) is the analytical standard of Raloxifene. This product is intended for research and analytical applications. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    Raloxifene (Standard)
  • HY-112746
    Etacstil

    DPC974; GW5638

    		 Estrogen Receptor/ERR Cancer
    Etacstil (GW5638) is a estrogen receptor antagonist that displays minimal uterotropic activity in ovariectomized rats and inhibits the agonist activity of Estradiol (HY-B0141), Tamoxifen (HY-13757A) and Raloxifene (HY-13738) in the environment. Etacstil is promising for research of breast cancer and bone protection .
    Etacstil
  • HY-13507R
    Lumiracoxib (Standard)

    		COX Metabolic Disease Inflammation/Immunology Cancer
    Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM . Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
    Lumiracoxib (Standard)
  • HY-N2098
    Obtusifolin

    		NF-κB Cancer
    Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway . Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein .
    Obtusifolin
  • HY-161084
    CSF1R-IN-18

    		c-Fms Neurological Disease Cancer
    CSF1R-IN-18 (Compdound 16t), para-aniline derivative, is a colony-stimulating factor 1 receptor (CSF1R) inhibitor. CSF1R-IN-18 can be used for the research of cancers, CNS-diseases and bone diseases .
    CSF1R-IN-18
  • HY-I0450
    Anticancer agent 265

    		Drug Derivative Cancer
    Anticancer agent 265 (compound 1) is an anticancer compound. Anticancer agent 265 exhibits in vitro anticancer activity against three human bone cancer lines, U2OS, Saos-2, and GC9811, with IC50 values ​​of 13.1, 11.7, and 14.6 μM, respectively .
    Anticancer agent 265
  • HY-N2098R
    Obtusifolin (Standard)

    		NF-κB Cancer
    Obtusifolin (Standard) is the analytical standard of Obtusifolin. This product is intended for research and analytical applications. Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway . Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein .
    Obtusifolin (Standard)
  • HY-153691
    BTB01303

    		mGluR Others
    BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain .
    BTB01303
  • HY-117182
    LG190178

    		Apoptosis VD/VDR RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
    LG190178
  • HY-N0088
    Apocynin
    20+ Cited Publications

    Acetovanillone

    		 NADPH Oxidase Metabolic Disease Inflammation/Immunology
    Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM . Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model . Apocynin can also be used for cancer research . Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass .
    Apocynin
  • HY-15147
    XAV-939
    Maximum Cited Publications
    142 Publications Verification

    		 β-catenin PARP Cancer
    XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .
    XAV-939
  • HY-W276106
    KM02894

    		Others Cancer
    KM02894 is an inhibitor of glutamate release. Cancer cells release high levels of glutamate, which disrupts normal bone turnover and may lead to cancer-induced bone pain. KM02894 can be used for cancer related research .
    KM02894
  • HY-N0088R
    Apocynin (Standard)

    		NADPH Oxidase Metabolic Disease Inflammation/Immunology
    Apocynin (Standard) is the analytical standard of Apocynin. This product is intended for research and analytical applications. Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM . Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model . Apocynin can also be used for cancer research . Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass .
    Apocynin (Standard)
  • HY-100701
    Dutacatib

    		Cathepsin SARS-CoV Virus Protease Infection Cancer
    Dutacatib is inhibitor for SARS-CoV-2 3CL pro and cathepsin K, which exhibits antiviral activity and ameliorates the cancer-induced bone diseases .
    Dutacatib
  • HY-132219
    N,N-Dipropyldopamine hydrobromide

    		mGluR Cancer
    N. N-dipropyrldopamine is a potent inhibitor of glutamate release and has anticancer activity. The increase of glutamate secretion leads to cancer-induced bone pain (CIBP). N. N-dipropyrldopamine plays an analgesic role in CIBP .
    N,N-Dipropyldopamine hydrobromide
  • HY-114631
    EM-800

    		Estrogen Receptor/ERR Cancer
    EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ). EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845). Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism .
    EM-800
  • HY-10537
    Laromustine

    VNP40101M

    		 DNA/RNA Synthesis Cancer
    Laromustine (VNP40101M) is a compound with antitumor activity. The mechanism of action of Laromustine mainly involves DNA alkylation and DNA repair inhibition. Laromustine can be used for bone marrow transplantation in patients with acute myeloid leukemia and cancer .
    Laromustine
  • HY-N0036
    Costunolide
    5+ Cited Publications

    (+)-Costunolide; Costus lactone

    		 Apoptosis Endogenous Metabolite Cancer
    Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells .
    Costunolide
  • HY-32337
    Tacalcitol
    3 Publications Verification

    1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3

    		 VD/VDR Interleukin Related Metabolic Disease Inflammation/Immunology Cancer
    Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) can promote normal bone growth by regulating calcium ions. Tacalcitol inhibits cancer cell proliferation and migration. Tacalcitol can be used in the research of inflammation, cancer, and skin diseases .
    Tacalcitol
  • HY-13556
    Arzoxifene

    LY353381; SERM III

    		 Estrogen Receptor/ERR Metabolic Disease Cancer
    Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile .
    Arzoxifene
  • HY-W088413A
    DOTA-amide dihydrate

    		Biochemical Assay Reagents Cancer
    DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .
    DOTA-amide dihydrate
  • HY-13738S
    Raloxifene-d4

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d4
  • HY-136990
    GLPG0259

    		Others Cancer
    GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .
    GLPG0259
  • HY-13738S2
    Raloxifene-d4 hydrochloride

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d4 hydrochloride
  • HY-13738S3
    Raloxifene-d10

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d10
  • HY-32337R
    Tacalcitol (Standard)

    1,24(R)-Dihydroxyvitamin D3 (Standard); 1.alpha.,24R-Dihydroxyvitamin D3 (Standard)

    		 VD/VDR Interleukin Related Metabolic Disease Inflammation/Immunology Cancer
    Tacalcitol (Standard) is the analytical standard of Tacalcitol. This product is intended for research and analytical applications. Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) can promote normal bone growth by regulating calcium ions. Tacalcitol inhibits cancer cell proliferation and migration. Tacalcitol can be used in the research of inflammation, cancer, and skin diseases.
    Tacalcitol (Standard)
  • HY-N0528
    Linarin

    Buddleoside; Linarine

    		 TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer .
    Linarin
  • HY-145441
    GEM–IB

    		Drug Derivative Cancer
    GEM–IB is the conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB). GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) .
    GEM–IB
  • HY-123310
    JNJ-26146900

    		Androgen Receptor Cancer
    JNJ-26146900 is a potent and orally active androgen receptor antagonist with a Ki value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer .
    JNJ-26146900
  • HY-13738S4
    Raloxifene-d10-1

    Keoxifene-d10; LY156758(free base)-d10; LY139481-d10

    		 Estrogen Receptor/ERR Cancer
    Raloxifene-d10-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].
    Raloxifene-d10-1
  • HY-15897
    LDN-212854
    1 Publications Verification

    		 TGF-β Receptor Cancer
    LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .
    LDN-212854
  • HY-119001
    BKM1644

    		Survivin Cancer
    BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .
    BKM1644
  • HY-N0036R
    Costunolide (Standard)

    		Apoptosis Endogenous Metabolite Cancer
    Costunolide (Standard) is the analytical standard of Costunolide. This product is intended for research and analytical applications. Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells .
    Costunolide (Standard)
  • HY-10635
    ABT-102

    		TRP Channel Inflammation/Immunology Cancer
    ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain .
    ABT-102
  • HY-N0528R
    Linarin (Standard)

    		TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Linarin (Standard) is the analytical standard of Linarin. This product is intended for research and analytical applications. Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer.
    Linarin (Standard)
  • HY-108694
    γ-Tocotrienol
    1 Publications Verification

    		 Endogenous Metabolite NF-κB Metabolic Disease Inflammation/Immunology
    γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .
    γ-Tocotrienol
  • HY-W130177
    Iodocholine iodide

    		Biochemical Assay Reagents Cancer
    Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .
    Iodocholine iodide
  • HY-W848341
    Clomesone

    NSC 338947; CIEtSoSo

    		 DNA Alkylator/Crosslinker Cancer
    Clomesone (NSC 338947) is a compound with antitumor activity. Clomesone induces the formation of cross-links between DNA strands in cell lines. Clomesone is inactive against most human colorectal cancer solid tumor cell lines in vitro, has no significant activity against mouse tumors in vivo, and is accompanied by bone marrow suppression. Its pharmacokinetic behavior indicates that it cannot reach effective concentrations at the tumor site.
    Clomesone
  • HY-P99259
    Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    		 c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
    Cabiralizumab
  • HY-132200
    UNC5293

    		TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3 Cancer
    UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .
    UNC5293
  • HY-110221
    Rp-8-pCPT-cGMPS sodium

    		PKG Neurological Disease
    Rp-8-pCPT-cGMPS sodium is the sodium salt form of Rp-8-pCPT-cGMPS. Rp-8-pCPT-cGMPS is an inhibitor for cGMP-dependent protein kinase (cGK). Rp-8-pCPT-cGMPS sodium is an agonist for cyclic nucleotide-gated (CNG) channels in a voltage-dependent manner .
    Rp-8-pCPT-cGMPS sodium
  • HY-147616
    CSF1R-IN-13

    		c-Fms Cancer
    CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .
    CSF1R-IN-13

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: